Folic Acid Interferes With Radiation Esophagitis

Lung Cancer Clinical Trial

Official title:

Randomized Controlled Clinical Study of Folic Acid Treatment of Radiation Esophagitis After Chemoradiation in Lung Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05296369
• Other study ID #: GZMU-FA
• Status: Recruiting
• Phase: N/A
• Start date: March 1, 2022
• Est. completion date: May 2023

Study information

• Verified date: March 2022
• Source: Guizhou Medical University
• Contact: Bing Lu, MD
• Phone: 13809432527
• Email: lbgymaaaa[@]sohu.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This randomized study compared the incidence and severity of radiation esophagitis with folic acid and with conventional symptomatic treatment.

Description:

By prospective randomized controlled study, this study research plans to recruit with diagnosis of lung cancer patients, according to whether there is drug intervention were divided into treatment group and control group, compared two groups of acute radiation esophagitis in the before and after the intervention, extent of occurrence of folic acid and clinical curative effect, so as to verify whether folic acid can be used as an intervention in the treatment of radioactive esophagitis, To explore the safety of folic acid in the treatment of radioactive esophagitis and explore the standardized treatment of radioactive esophagitis.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 90
• Est. completion date: May 2023
• Est. primary completion date: May 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Patients with malignant lung cancer (incluedig Non-small cell lung cancer, small cell lung cancer) diagnosed by histopathology or cytology.

2. TNM Stage N2~N3 (IASLC International TNM staging standard for Lung Cancer, 8th edition) was indicated by radiotherapy and the patients were treated for the first time.

3. Aged between 18 and 75 years old,no limit on the gender.

4. ECOG=2 or KPS=70.

5. No contraindication of Concurrent chemoradiotherapy.

6. Patients without important organ dysfunction,hematology: it is within the normal range according to the standards of each laboratory; Cardiac function: normal range; Liver function: normal range; Renal function: normal range; Pulmonary function: FEV1 > 50%, mild to moderate impairment of pulmonary function.

7. Patients with good compliance to treatment received and follow-up.

Exclusion Criteria:

1. Prior to treatment, there were other esophageal diseases, such as gastrointestinal ulcer, reflux esophagitis, cardia relaxation.

2. Patients with severe nutritional anemia prior to treatment.

3. The IV stage patients with uncontrolled malignant pleural effusion,with diffuse liver or lung metastasis which lead to liver or pulmonary dysfunction.

4. Patients with severe heart, lung or kidney diseass,such as uncontrolled hypertension, diabetes, unstable angina, a history of myocardial infarction or heart failure, or uncontrolled arrhythmias; There is clearly clinically diagnosed heart valve disease; The active phase of a bacterial, fungal, or viral infection; Mental disorders; Severely impaired lung function.

5. A history of previous tumors complicated with other malignant tumors.

6. The pregnant or breast-feeding patients.

7. Patients with mental and neurological diseases.

Related Conditions & MeSH terms

• Esophagitis
• Lung Cancer
• Lung Neoplasms

Intervention

Drug:
• Folic acid
Folic acid was added during the period prior to concurrent chemoradiotherapy

Locations

Country	Name	City	State
China	The Affiliated Cancer Hospital of Guizhou Medical University	Guiyang	Guizhou

Sponsors (1)

Lead Sponsor	Collaborator
Guizhou Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Progression-free survival(PFS)	PFS is defined as the duration of time from start of treatment to time of progression or death, whichever occurs first.	up to 12 months
Secondary	Severity of radiation esophagitis	A modified NCI-CTC score (the sum of dysphagia pain score and dysphagia pain score) was used to evaluate the occurrence of radioactive esophagitis.	day 1 up to 4 weeks after the end of treatment
Secondary	Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	To assess and record nausea, vomiting, hematologic toxicity,radiation pneumonitis and other treantment complications by CTCAE v5.0.Hematotoxicity includes white blood cell count (The normal range count is 3.5 to 9.5×10^9/L), neutrophil count(The normal range count is 1.8 to 6.3×10^9/L), platelet count(The normal range count is 125 to 350×10^9/L), hemoglobin count(The normal range count is 115 to 175g/L),measuring creatinine value(The normal value of creatinine is 44to106µmol/L), endogenous creatinine clearanceThe normal value of creatinine is 80 to120 mo/min), bilirubin(Including total bilirubin, direct bilirubin and indirect bilirubin,), aspartate aminotransferase(AST, The normal value of AST is 13 to 40u/L)and alanine aminotransferase(ALT, The normal value of ALT is 7 to 50u/L).The severity of radiational pneumonitis can be evaluated by the Radiation Therapy Oncology Group(RTOG)morbidity grading criteria.	day 1 up to 4 weeks after the end of treatment